We asked you to share one word on why epilepsy is more than seizures. This is what you had to say! #epilepsyday

Philadelphia landmarks light up this evening for #RareDiseaseDay2021 thanks to Marinus @GregoryFCA. Other locations include: One and Two Liberty Place, Lincoln Financial Field, Boathouse Row, Pennsylvania Convention Center, Wells Fargo Center, Subaru of America

We're marking #WorldCDKL5Day by celebrating the #CDD community of children, families, and advocates who drive our mission forward each and every day. Learn more about CDD and the ways you can get involved: cdkl5.com/cdkl5-resource… #CDDAwarenessMonth #CDKL5Forward #CDD

Feels like a lifetime, but just four years after leaving the Bloomberg newsroom, I now have my own B-Unit and access to the terminal. Gone from an employee to a client. Now, if only I could remember all the functions! Bloomberg Bloomberg

Furthering our commitment to advancing innovative treatment options for patients with seizure disorders, Marinus is thrilled to announce its exclusive collaboration with Orion Pharma for European commercialization of investigational ganaxolone. businesswire.com/news/home/2021…

Proud of all the teamwork behind the scenes to be able to announce these achievements! @MRNS After struggling with its sole drug for years, Marinus rides positive data to a commercialization deal in Europe - endpts.com/after-struggli…

After Years Of Setbacks, Marinus Closes In On Rare Epilepsy Opportunity bit.ly/3rWZLZ5 #PharmaScrip

Thrilled for Marinus CEO to be part of this Endpoints News presentation today

With all the attributes of a strong biotech leader, comprising of an innovative nature, empathy & patient-centricity, we're proud to have our CEO ranked among these inspiring executives $MRNS Top 25 Biotech CEOs of 2022 | The Healthcare Technology Report thehealthcaretechnologyreport.com/the-top-25-bio…

Thank you Tracy Beth Høeg, MD, PhD for continuing to address challenges in #raredisease drug development so that companies dedicated to rare diseases can bring scientific #innovation to patients with urgent medical needs. #OneRareVoice

Today, the FDA approved our treatment for seizures associated with #CDKL5 deficiency disorder (CDD) in patients two years of age and older, marking the first approved treatment indicated specifically for seizures in this rare form of epilepsy. Learn more: bit.ly/3CV1ljH

I’m so honored to be part of an FDA approval of our first treatment. It has been amazing to work with the patient communities, the advocacy groups, our regulatory, clinical, scientific, legal and all the other team Marinus 🎉

We are thrilled to share this news with our community! Successfully completing a clinical trial in a rare disease like ours is an incredible feat, and an announcement about the 1st ever targeted seizure drug to treat #CDKL5 Deficiency Disorder is certainly something to celebrate!

Our CEO, Scott Braunstein, talks about the importance of today’s FDA approval. Our treatment for seizures associated with #CDKL5 deficiency disorder (CDD) is now FDA approved in patients two years of age and older. Read more: bit.ly/3CV1ljH

We’re excited to share The Lancet Neurology has published pivotal Phase 3 results for our investigational medicine for the treatment of seizures associated with #CDKL5 deficiency disorder (CDD). bit.ly/3vp4C7M

When Marinus Pharmaceuticals completed its turnaround and finally pushed its sole drug across the FDA finish line, the company noted it would sell the priority review voucher it received for its efforts. On Thursday, Marinus revealed the buyer. endpts.com/novo-nordisk-n…

I am delighted to announce the launch of Damouni Group, a force in strategic communications, corporate affairs and content creation. Thank you to all who have supported me on this journey! businesswire.com/news/home/2024…

To put these new $AKRO data into context, patients with cirrhosis due to MASH have a severe form of the disease with few treatment options outside of a liver transplant. Once MASH progresses to cirrhosis, median survival is about five years, three times shorter than for

Interesting deal with GSK paying $1.2b upfront to license a mid-stage MASH drug from Sophie Kornowski's Boston Pharmaceuticals. Quite an endorsement of the Ph2 data in hand. Sophie was John Reed's BD chief at Roche back in the day. Clearly, she learned a lot. Elizabeth Cairns has

Announcing “K-Dense”, a multi-agent AI scientist that has already made a new discovery in aging research 🧵 Ashwin Gopinath & @BioStateAI tinyurl.com/3dmraa5k